Authorities in 27 European countries have approved GRAZAX® as a disease modifying allergy treatment. GRAZAX® is now the only registered tablet treatment against grass pollen allergy with documented sustained effect after completion of treatment. The approval and the extended marketing authorisation are based on the results of the first follow-up year in a long-term study (GT-08) with GRAZAX® published at the European allergy congress in June 2009. The results document that the significant improvement of the patients' eye and nose symptoms and quality of life is sustained after completion of the recommended treatment regimen. The patients in the GT-08 study have adhered to the recommended three-year GRAZAX® treatment regimen and completed treatment in the autumn of 2007. The 2008 pollen season was thus the first follow-up year in which the patients did not receive active treatment with GRAZAX®. The results represent a major breakthrough, since ALK is the first company ever to document a sustained disease modifying effect of an allergy immunotherapy tablet (AIT). Patients cannot obtain such a sustained disease modifying effect with traditional symptom-relieving allergy medication such as antihistamines and/or nasal corticosteroids. This announcement does not change ALK's financial outlook for 2009. ALK-Abelló A/S Jens Bager President & CEO For further information please contact: Per Plotnikof, Head of Investor Relations, tel: +45 2261 2525